Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 4,001–4,100 of 15,747
Ahmed, S., & Herschhorn, A. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-24 · Cited by 32
“…response is most commonly elicited against soluble proteins and/or Envs on the surface of viruses (or bacteria), current FDA-approved SARS-CoV-2 mRNA vaccines (e.g., BNT162b2) contain RNA that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike glycoprotein (122).”
Myocarditis after COVID‐19 mRNA vaccination: A systematic review of case reports and case series
Park, D. Y., An, S., Kaur, A., Malhotra, S., & Vij, A. (2022) · Clinical Cardiology · doi:10.1002/clc.23828 · Cited by 26
“Phase 3 trials of COVID‐19 mRNA vaccines did not detect any major vaccine‐associated myocarditis.(78,79) While there maybe apprehension among some patients and providers, the benefits of COVID‐19 vaccination at preventing severe COVID‐19 infections cannot be emphasized enough.”
BackgroundLi, R., Zhao, Y., Fan, H., Zhou, H., Yin, S., Zhang, Q., Jin, M., Liu, G. L., & Huang, L. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202306145 · Cited by 26
Genomic medicine for liver disease
Zheng, M., Allington, G., & Vilarinho, S. (2022) · Hepatology · doi:10.1002/hep.32364 · Cited by 28
Rare cutaneous adverse effects of COVID‐19 vaccines: a case series and review of the literature
Annabi, E., Dupin, N., Sohier, P., Garel, B., Franck, N., Aractingi, S., Guégan, S., & Oulès, B. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17578 · Cited by 24
Antibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 26
“Interestingly, similar to patients with extended COVID-19 infection, vaccination with the Pfizer mRNA vaccine induces long-lasting germinal center responses (Turner et al., 2021), suggesting that extended germinal center responses may be an important factor in the development of high quality neutralizing responses (La…”
InfluentialmRNA Vaccine: How to Meet the Challenge of SARS-CoV-2
Jin, Y., Hou, C., Li, Y., Zheng, K., & Wang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.821538 · Cited by 25
Numbers of spontaneous reports: How to use and interpret?
Kant, A. C., van Hunsel, F. P. A. M., & van Puijenbroek, E. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15024 · Cited by 25
Schmitt, S., Huppertsberg, A., Klefenz, A., Kaps, L., Mailänder, V., Schuppan, D., Butt, H., Nuhn, L., & Koynov, K. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.1c01407 · Cited by 28
Wang, X., Chen, X., Tan, J., Yue, S., Zhou, R., Xu, Y., Lin, Y., Yang, Y., Zhou, Y. W., Deng, K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.03.035 · Cited by 27
COVID-19 Vaccinations in EMS Professionals: Prevalence and Predictors
Gregory, M. E., Powell, J. R., MacEwan, S. R., Kurth, J. D., Kenah, E., Panchal, A. R., & McAlearney, A. S. (2021) · Prehospital Emergency Care · doi:10.1080/10903127.2021.1993391 · Cited by 26
Real-World Safety of COVID-19 mRNA Vaccines: A Systematic Review and Meta-Analysis
Xu, W., Ren, W., Wu, T., Wang, Q., Luo, M., Yi, Y., & Li, J. (2023) · Vaccines · doi:10.3390/vaccines11061118 · Cited by 31
“Both mRNA vaccines showed high efficacy and mild to moderate adverse events (AEs) in phase 3 randomized clinical trials (RCTs) [4,5].”
BackgroundResultInfluentialmRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity
Kenney, L. L., Chiu, R. S.-Y., Dutra, M. N., Wactor, A., Honan, C., Shelerud, L. M., Corrigan, J. J., Yu, K. J., Ferrari, J. D., Jeffrey, K. L., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101717 · Cited by 29
Li, F. F., Liu, A. C., Gibbs, E., Tanunliong, G., Marquez, A. C., Gantt, S. M., Frykman, H., Krajden, M., Morshed, M. G., Prystajecky, N., et al. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.105050 · Cited by 24
Global COVID-19 vaccination challenges: Inequity of access and vaccine hesitancy
Dagovetz, M., Momchilov, K., Blank, L., Khorsandi, J., Rizzo, A., Khabbache, H., Sitibondo, A., Gómez-Salgado, J. C., Chirico, F., & Batra, K. (2025) · Journal of Medicine Surgery and Public Health · doi:10.1016/j.glmedi.2025.100197 · Cited by 39
Longevity of vaccine protection: Immunological mechanism, assessment methods, and improving strategy
Chen, Z., Gao, X., & Yu, D. (2022) · View · doi:10.1002/viw.20200103 · Cited by 34
Hahn, W. O., & Wiley, Z. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.01.008 · Cited by 29
Role of N6‐methyladenosine RNA modification in cancer
Qu, Y., Gao, N., Zhang, S., Gao, L., He, B., Wang, C., Gong, C., Shi, Q., Li, Z., Yang, S., et al. (2024) · MedComm · doi:10.1002/mco2.715 · Cited by 31
“318 In addition to infectious diseases, the potent preventive and therapeutic value of mRNA vaccines in oncology is unclear and attractive.”
BackgroundNiazi, S. K., & Magoola, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312883 · Cited by 30
“The first human disease linked to miRNA dysregulation was chronic lymphocytic leukemia [106], and since then, numerous miRNAs associated with cancer have been termed as “oncomiRs” [107].”
Fritsche, L. G., Jin, W., Admon, A. J., & Mukherjee, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12041328 · Cited by 26
Paireau, J., Charpignon, M., Larrieu, S., Calba, C., Hozé, N., Boëlle, P., Thiébaut, R., Prague, M., & Cauchemez, S. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08106-1 · Cited by 25
“For first-dose vaccination, we applied an 18-day lag (12 days for the build-up of immunity [23] and 6 days for the delay between symptom onset and hospital admission).”
MethodCho, K., Park, S., Kim, E. Y., Koyanagi, A., Jacob, L., Yon, D. K., Lee, S. W., Kim, M. S., Raduà, J., Elena, D., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27828 · Cited by 28
Update on the COVID-19 Vaccine Research Trends: A Bibliometric Analysis
Xu, Z., Qu, H., Ren, Y., Gong, Z., Ri, H., Zhang, F., Chen, X., Zhu, W., Shao, S., & Chen, X. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s335745 · Cited by 27
Chemaitelly, H. S., Ayoub, H. H., Coyle, P. V., Tang, P., Hasan, M. R., Yassine, H. M., Thani, A. A. A., Kanaani, Z. A., Al‐Kuwari, E., Jeremijenko, A. M., et al. (2025) · eLife · doi:10.7554/elife.103690 · Cited by 33
“The immunization campaign was launched on December 21, 2020, with the BNT162b2 vaccine ( Polack et al., 2020 ), and 3 months later, the mRNA-1273 vaccine ( Baden et al., 2021 ) was added.”
Padoan, A., Cosma, C., Bonfante, F., Rocca, F. D., Barbaro, F., Santarossa, C., Dall’Olmo, L., Pagliari, M., Bortolami, A., Cattelan, A. M., et al. (2021) · Clinica Chimica Acta · doi:10.1016/j.cca.2021.10.028 · Cited by 22
“Results from clinical trials demonstrate its efficacy in preventing symptomatic coronavirus disease 2019 (COVID-19) [1] as well as the increase achieved in detectable anti-SARS-CoV-2 antibodies in the serum of vaccinated individuals [2].”
BackgroundInfluentialImai, N., Hogan, A. B., Williams, L. R., Cori, A., Mangal, T. D., Winskill, P., Whittles, L. K., Watson, O. J., Knock, E., Baguelin, M., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16992.1 · Cited by 25
Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission
Swan, D. A., Goyal, A., Bracis, C., Moore, M., Krantz, E. M., Brown, E. R., Ojeda, E. F. C., Reeves, D. B., Gao, F., Gilbert, P. B., et al. (2021) · Viruses · doi:10.3390/v13101921 · Cited by 27
“7 which had estimated VEDIS = 95% and 90%, respectively [4,5].”
BackgroundSchmidt, K. G., Harrer, E. G., Taşçılar, K., Kübel, S., Kenz, B. E., Hartmann, F., Simón, D., Schett, G. A., Nganou‐Makamdop, K., & Harrer, T. (2022) · Viruses · doi:10.3390/v14030651 · Cited by 32
“In summary, our study clearly demonstrates that the BNT162b2 mRNA vaccine induces a robust SARS-CoV2 spike specific humoral immune response both in HIV-1uninfected subjects and in HIV-1-infected patients on antiretroviral therapy, exceeding the antibody response observed in SARS-CoV-2 infected subjects.”
MethodInfluentialThe impact of SARS-CoV-2 vaccination in Dravet syndrome: A UK survey
Clayton, L. M. S., Balestrini, S., Cross, J. H., Wilson, G., Eldred, C., Evans, H. S., Koepp, M. J., & Sisodiya, S. M. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108258 · Cited by 26
“This is markedly different from that reported in phase 2/3 trials, where only 4% and 24% of those receiving the Pfizer/BioNTech and Oxford/AstraZeneca vaccine, respectively, reported fever [16,17].”
BackgroundMethodResultInfluentialComparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50
Xie, J., Feng, S., Li, X., Gea‐Mallorquí, E., Prats‐Uribe, A., & Prieto‐Alhambra, D. (2022) · Nature Communications · doi:10.1038/s41467-022-29159-x · Cited by 24
“The decision-making for these anchor windows was based on (1)”
MethodThe Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19
Itaya, T., Isobe, Y., Suzuki, S., Koike, K., Nishigaki, M., & Yamamoto, Y. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.2973 · Cited by 29
Yang, W., Miyazaki, T., Nakagawa, Y., Boonstra, E., Masuda, K., Nakashima, Y., Chen, P., Mixich, L., Barthelmes, K., Matsumoto, A., et al. (2023) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2023.2170164 · Cited by 22
“Moreover, the recent approvals of SARS-CoV-2 vaccines confirmed the clinical applicability of mRNA [4,5].”
BackgroundSunohara, S., Asakura, T., Kimura, T., Ozawa, S., Oshima, S., Yamauchi, D., & Tamakoshi, A. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257107 · Cited by 30
“95 [31] VE& Vaccine efficacy for death.”
In the Era of mRNA Vaccines, Is There Any Hope for HIV Functional Cure?
Esteban, I., Pastor-Quiñones, C., Usero, L., Plana, M., García, F., & Leal, L. (2021) · Viruses · doi:10.3390/v13030501 · Cited by 26
Adverse Events with the Pfizer-BioNTech COVID-19 Vaccine among Korean Healthcare Workers
Im, J. H., Kim, E., Lee, E., Seo, Y., Lee, Y., Jang, Y., Yu, S.-Y., Maeng, Y., Park, S., Park, S., et al. (2021) · Yonsei Medical Journal · doi:10.3349/ymj.2021.62.12.1162 · Cited by 24
“1162 States.(5) However, most of these data were obtained from Caucasian or American-African individuals, with only limited data obtained from Asian individuals.”
BackgroundInfluentialMouri, M., Imamura, M., Suzuki, S., Kawasaki, T., Ishizaki, Y., 櫻井恵一, Nagafuchi, H., Matsumura, N., Uchida, M., Ando, T., et al. (2022) · Allergology International · doi:10.1016/j.alit.2022.05.007 · Cited by 26
FAM13A as potential therapeutic target in modulating TGF-β-induced airway tissue remodeling in COPD
Tam, A., Leclair, P., Li, L. V., Yang, C. X., Li, X., Witzigmann, D., Kulkarni, J. A., Hackett, T., Dorscheid, D. R., Singhera, G. K., et al. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00477.2020 · Cited by 26
Plüß, M., Mese, K., Kowallick, J. T., Schuster, A., Tampe, D., & Tampe, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.784145 · Cited by 27
“As the coronavirus disease 2019 (COVID-19) pandemic is ongoing and new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are emerging, there is an urgent need for vaccines to protect individuals at high risk for complications and to potentially control disease outbreaks by herd immunity (1,…”
BackgroundImmune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
Zhang, Y., Ndzouboukou, J. B., Gan, M., Lin, X., & Fan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771242 · Cited by 26
Targeting Wnt-β-Catenin Signaling Pathway for Hepatocellular Carcinoma Nanomedicine
Bakrania, A. K., To, J. C., Zheng, G., & Bhat, M. (2023) · Gastro Hep Advances · doi:10.1016/j.gastha.2023.07.012 · Cited by 26
Beeraka, N. M., Tulimilli, S. V., Karnik, M., Sadhu, S. P., Pragada, R. R., Aliev, G., & Madhunapantula, S. V. (2021) · BioMed Research International · doi:10.1155/2021/8160860 · Cited by 27
“, pain, redness, fatigue, joint pain, and muscle pain within 1 to 2 days of vaccination [211].”
BackgroundA case of trigeminal neuralgia developing after a COVID-19 vaccination
Kaya, A., & Kaya, S. Y. (2021) · Journal of NeuroVirology · doi:10.1007/s13365-021-01030-7 · Cited by 24
Kawasuji, H., Morinaga, Y., Tani, H., Saga, Y., Kaneda, M., Murai, Y., Ueno, A., Miyajima, Y., Fukui, Y., Nagaoka, K., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00561-21 · Cited by 24
“This vaccine was shown to have preventive effects against COVID-19 in 95% of individuals (1); however, SARS-CoV-2 variants have emerged since this report.”
BackgroundSARS-CoV-2 immunity and vaccine strategies in people with HIV
Mullender, C., da Costa, K., Alrubayyi, A., Pett, S. L., & Peppa, D. (2022) · Oxford Open Immunology · doi:10.1093/oxfimm/iqac005 · Cited by 26
“Additionally, there was no significant difference in BNT162b2-elicited SARS-CoV-2 binding antibody levels to the Beta, Alpha and Gamma variants.”
InfluentialRational preparation and application of a mRNA delivery system with cytidinyl/cationic lipid
Li, L., Long, J., Sang, Y., Wang, X., Zhou, X., Pan, Y., Cao, Y., Huang, H., Yang, Z., Yang, J., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.10.023 · Cited by 24
“Though mRNA vaccines seem to be with good safety profiles in theory, adverse reactions were still reported after vaccine receipts [2,4,6,7].”
Parums, D. V. (2021) · Medical Science Monitor · doi:10.12659/msm.932899 · Cited by 24
Chin, E. T., Leidner, D., Zhang, Y., Long, E., Prince, L., Schrag, S. J., Verani, J. R., Wiegand, R. E., Alarid‐Escudero, F., Goldhaber‐Fiebert, J. D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1032 · Cited by 27
“Augmenting efficacy evidence from clinical trials [1, 2], observational studies among healthcare workers [3, 4], adults aged ≥65 years [5], and the general community [6, 7] have reported levels of protection from full vaccination ranging from 89% to 95%.”
BackgroundGualano, B., Lemes, Í. R., da Silva, R. P., Pinto, A. J., Mazzolani, B. C., Smaira, F. I., Sieczkowska, S. M., Aikawa, N. E., Pasoto, S. G., Ribeiro, A. C. D. M., et al. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.12.016 · Cited by 37
Hassan, T. A., Sáenz, J. E., Dučinskienė, D., Cook, J. P., Imperato, J., & Zou, K. H. (2021) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s313626 · Cited by 32
Hajji, Y. A., Taylor, H., Starkey, T., Lee, L. Y. W., & Tilby, M. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01951-y · Cited by 28
Shahrear, S., & Islam, A. B. M. M. K. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10515-4 · Cited by 25
“1% by mRNA-1273 vaccine [91] and 95% by BNT162b2 vaccine [92]) while the viral vectored vaccine showed a lower efficacy (70·4% by ChAdOx1 nCoV-19 vaccine [93]).”
BackgroundBello‐Chavolla, O. Y., Antonio‐Villa, N. E., Valdés‐Ferrer, S. I., Fermín‐Martínez, C. A., Fernández‐Chirino, L., Vargas‐Vázquez, A., Ramírez‐García, D., Mancilla-Galindo, J., Kammar‐García, A., Ávila‐Funes, J. A., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.01.040 · Cited by 34
“[8] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic
Tsakiri, M., Naziris, N., & Demetzos, C. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121212 · Cited by 25
COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran
Vaezi, A., & Meysamie, A. (2021) · Vaccines · doi:10.3390/vaccines10010037 · Cited by 26
Vaccine Therapy in Non-Small Cell Lung Cancer
García-Pardo, M., Gorría, T., Malenica, I., Corgnac, S., Teixidó, C., & Mezquita, L. (2022) · Vaccines · doi:10.3390/vaccines10050740 · Cited by 28
“Several mRNA vaccines platforms are under development in the cancer setting, and there has been renewed interest in mRNA technology as a result of the success of the SARS-CoV-2 vaccines [67].”
BackgroundFan, J., Yang, Y., Grimstein, M., Zhang, X., Kitabi, E. N., Earp, J. C., Arya, V., Reynolds, K. S., Zhu, H., & Wang, Y. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2445 · Cited by 24
Papadokostaki, E., Tentolouris, A., Anastasiou, I. A., Psichοgiou, M., Iliaki, E., Eleftheriadou, I., Hatzakis, A. E., & Tentolouris, N. (2022) · Vaccines · doi:10.3390/vaccines10030382 · Cited by 25
“The mRNA-based BNT162b2 vaccine has demonstrated high efficacy against severe SARS-CoV-2 [9].”
BackgroundPolicy Stringency, Handwashing and COVID-19 cases: Evidence from Global dataset
Dzator, J., Acheampong, A. O., Dzator, M., Paolucci, F., Yawe, B. L., Asmah, E. E., Andoh, F. K., Kabagenyi, A., & Gillespie, J. (2021) · Health Policy and Technology · doi:10.1016/j.hlpt.2021.100574 · Cited by 31
3D Lung Tissue Models for Studies on SARS-CoV-2 Pathophysiology and Therapeutics
Plebani, R., Bai, H., Si, L., Li, J., Zhang, C., & Romano, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710071 · Cited by 25
Malki, A., Atlam, E., Hassanien, A. E., Ewis, A. A., Dagnew, G., & Gad, I. (2022) · Alexandria Engineering Journal · doi:10.1016/j.aej.2022.05.051 · Cited by 24
Chen, C., Lai, C.-C., Luh, D., Chuang, S., Yang, K., Yeh, Y., Yen, A. M., Chang, K., Chang, R., & Chen, S. L. (2021) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2021.05.022 · Cited by 28
Adverse Events following Immunization with COVID‐19 Vaccines: A Narrative Review
Bhandari, B., Rayamajhi, G., Lamichhane, P., & Shenoy, A. K. (2022) · BioMed Research International · doi:10.1155/2022/2911333 · Cited by 30
“0023%) of paroxysmal ventricular arrhythmia was identified among the 43,252 participants of a trial who received a single dose of PfizerBioNTech COVID-19 vaccine [59].”
Functional Involvement of circRNAs in the Innate Immune Responses to Viral Infection
Maarouf, M., Wang, L., Wang, Y., Rai, K. R., Chen, Y., Fang, M., & Chen, J. (2023) · Viruses · doi:10.3390/v15081697 · Cited by 26
Expert consensus on COVID-19 vaccination in children
Zheng, Y., Wang, X., Feng, L.-Z., Xie, Z., Jiang, Y., Lu, G., Li, X., Jiang, R., Deng, J.-K., Liu, M., et al. (2021) · World Journal of Pediatrics · doi:10.1007/s12519-021-00465-6 · Cited by 29
Furer, V., Eviatar, T., Zisman, D., Peleg, H., Braun‐Moscovici, Y., Balbir‐Gurman, A., Paran, D., Levartovsky, D., Zisapel, M., Elalouf, O., et al. (2022) · Vaccines · doi:10.3390/vaccines10060901 · Cited by 27
Widman, A. J., Cohen, B., Park, V., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7048 · Cited by 24
Pálinkás, A., & Sándor, J. (2022) · Vaccines · doi:10.3390/vaccines10071009 · Cited by 27
“Vaccine availability and the publication of safety and efficacy reports determined the timing of vaccine introduction into the Hungarian vaccination program (26/12/2020 Pfizer-BioNTech COVID-19 mRNA vaccine [22]; 16 January 2021 Moderna COVID-19 mRNA-1273 vaccine [23]; 9 February 2021 Oxford/AstraZeneca COVID-19 vacci…”
BackgroundDesigning the Next Generation of Biomaterials through Nanoengineering
Davis, R., Duggal, I., Peppas, N. A., & Gaharwar, A. K. (2025) · Advanced Materials · doi:10.1002/adma.202501761 · Cited by 31
COVID-19 vaccines - are we there yet?
McIntyre, P. B., Joo, Y. J., Chiu, C., Flanagan, K. L., & Macartney, K. K. (2020) · Australian Prescriber · doi:10.18773/austprescr.2020.084 · Cited by 27
Galindo, R. A. R., Chow, H., & Rongkavilit, C. (2021) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2021.05.004 · Cited by 31
“This is a double-blinded randomized trial of 43,448 persons ages 16 years or older who either received a 2-dose placebo or a 2-dose 30 mg BNT162b2 vaccine spaced apart by 21 days.(49) The results demonstrated a 95% efficacy at preventing symptomatic COVID-19.”
Jurdi, A. A., Gassen, R. B., Borges, T. J., Solhjou, Z., Hullekes, F. E., Lape, I. T., Efe, O., Alghamdi, A. S. A., Patel, P., Choi, J. Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.838985 · Cited by 25
“Despite diminished anti-viral antibody and cellular responses, we found that the absolute risk of developing symptomatic SARSCoV-2 infection post-vaccination was higher, albeit with very small numbers, than previously reported in immunocompetent individuals (54, 55).”
BackgroundResultUmar, A. K., Zothantluanga, J. H., Luckanagul, J. A., Limpikirati, P. K., & Sriwidodo, S. (2023) · PeerJ · doi:10.7717/peerj.14915 · Cited by 28
“COVID-19 initially emerged from Wuhan, How to cite this article Kakhar Umar A, Zothantluanga JH, Luckanagul JA, Limpikirati P, Sriwidodo S. 2023.”
BackgroundInfluentialPaternina-Caicedo, Á. J., Jit, M., Alvis‐Guzmán, N., Fernández, J. C., Hernández, J., Paz-Wilches, J., Rojas-Suárez, J. A., Castell, C. R. D., Alvis-Zakzuk, N. J., Smith, A. D., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100296 · Cited by 26
COVID-19 Vaccines: Current Conditions and Future Prospects
Zieneldien, T., Kim, J., Cao, J. A., & Cao, C. (2021) · Biology · doi:10.3390/biology10100960 · Cited by 25
“This technology has been utilized by both Moderna and Pfizer-BioNTech (Pfizer) mRNA vaccines, which use ionizable cationic lipids that encapsulate the nucleosidemodified mRNA encoding a spike protein of SARS-CoV-2 [109].”
MethodPrüβ, B. M. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2702065 · Cited by 28
“It was shown that sera from 20 patients that had received two doses of the BioNTech/Pfizer vaccine in the phase I/phase II trial [57] showed no reduction in virus neutralizing activity between the N501Y variant and the original SARS CoV-2 [58].”
BackgroundLippi, G., Sciacovelli, L., Trenti, T., & Plebani, M. (2021) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2021-0038 · Cited by 22
Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection
Rolland, M., & Gilbert, P. B. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009406 · Cited by 22
A Post-Pandemic Enigma: The Cardiovascular Impact of Post-Acute Sequelae of SARS-CoV-2
Singh, T. K., Zidar, D. A., McCrae, K. R., Highland, K. B., Englund, K., Cameron, S. J., & Chung, M. K. (2023) · Circulation Research · doi:10.1161/circresaha.122.322228 · Cited by 29
The behavioral immune system and vaccination intentions during the coronavirus pandemic
Karlsson, L. C., Soveri, A., Lewandowsky, S., Karlsson, L., Karlsson, H., Nolvi, S., Karukivi, M., Lindfelt, M., & Antfolk, J. (2021) · Personality and Individual Differences · doi:10.1016/j.paid.2021.111295 · Cited by 24
Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19
Scarabel, L., Guardascione, M., Bo, M. D., & Toffoli, G. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.01.035 · Cited by 28
Ziegler, L., Klemis, V., Schmidt, T., Schneitler, S., Baum, C., Neumann, J., Becker, S. L., Gärtner, B. C., Sester, U., & Sester, M. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104743 · Cited by 25
Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity
Spini, A., Giudice, V., Brancaleone, V., Morgese, M. G., Francia, S. D., Filippelli, A., Ruggieri, A., Ziche, M., Ortona, E., Cignarella, A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105848 · Cited by 26
“…has been observed in men for the two genomic vaccines (Pfizer, 96.4% in males vs. 93.7% in females; and Moderna, 95.4% in males vs. 93.1% in females, respectively) [165,166] as well as for the adenoviral vector-based vaccine (Sputnik, 94.2% in males vs. 87.5% in females, respectively) [168].”
InfluentialSato, Y., Nakamura, T., Yamada, Y., & Harashima, H. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.05.006 · Cited by 28
Delivering mRNA to a human NK cell line, NK-92 cells, by lipid nanoparticles
Nakamura, T., Nakade, T., Sato, Y., & Harashima, H. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122810 · Cited by 25
Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics
Pavan, M., & Moro, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054401 · Cited by 27
“Despite the poor performances of the first class of vaccines [70,71], several independent studies have asserted worldwide the efficacy of vaccination campaigns based on the other two types of vaccines, particularly in the case of mRNA-based ones [72,73].”
Background(2021) · doi:10.1101/2021.12.24.21268378 · Cited by 24
“Pfizer/BioNtech BNT162b2(16), and Sinovac CoronaVac (17), all profiled at peak immunogenicity 75 (see methods).”
BackgroundInfluentialKalafat, E., O’Brien, P., Heath, P. T., Doaré, K. L., von Dadelszen, P., Magee, L. A., Ladhani, S. N., & Khalil, A. A. (2021) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.23631 · Cited by 27
Jeong, S., Lee, N., Lee, S. K., Cho, E., Hyun, J., Park, M.-J., Song, W., Jung, E. J., Woo, H., Seo, Y. B., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01105-21 · Cited by 27
“To date, 52 early data have been reported on the immunogenicity and safety of the vaccine (4-9), but 53”
BackgroundZarębska‐Michaluk, D., Hu, C., Brzdęk, M., Flisiak, R., & Rzymski, P. (2022) · Vaccines · doi:10.3390/vaccines10081223 · Cited by 24
Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species
Peng, L., Fang, Z., Renauer, P. A., McNamara, A., Park, J. J.-Y., Lin, Q., Zhou, X., Dong, M. B., Zhu, B., Zhao, H., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111160 · Cited by 27
“The COVID-19 pandemic urged an international effort for rapid development of vaccines against SARS-CoV-2 (Tregoning et al., 2021), leading to multiple successful candidates including the highly efficacious mRNA vaccines (Baden et al., 2021; Polack et al., 2020).”
BackgroundMethodInfluentialNordström, P., Ballin, M., & Nordström, A. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4000584 · Cited by 24
Nomah, D. K., Reyes‐Urueña, J., Llibre, J. M., Ambrosioni, J., Ganem, F., Miró, J. M., & Casabona, J. (2021) · Current HIV/AIDS Reports · doi:10.1007/s11904-021-00579-6 · Cited by 26
“Regarding mRNA vaccines, in the Moderna and Pfizer trials [55, 56], only 0.”
BackgroundLu, Y., Qian, C., Huang, Y., Ren, T., Xie, W., Xia, N., & Li, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145501 · Cited by 31
Carter-Timofte, M. E., Arulanandam, R., Kurmasheva, N., Fu, K., Laroche, G., Taha, Z., van der Horst, D., Cassin, L., van der Sluis, R. M., Palermo, E., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00278 · Cited by 25
Seiffert, P., Konka, A., Kasperczyk, J., Kawa, J., Lejawa, M., Maślanka-Seiffert, B., Zembala-John, J., Bugdol, M. N., Romanik, M. K., Bułdak, R. J., et al. (2021) · Biogerontology · doi:10.1007/s10522-021-09944-9 · Cited by 26
Valcourt, E. J., Manguiat, K., Robinson, A., Lin, Y.-C., Abe, K. T., Mubareka, S., Shigayeva, A., Zhong, Z., Girardin, R. C., Dupuis, A. P., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00886-21 · Cited by 24
“clinical trials (11, 12), as well as hundreds of other vaccine candidates in different stages”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.